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Sporotrichosis is a chronic subcutaneous mycosis that affects both humans and animals
worldwide. This subcutaneous mycosis had been attributed to a single etiological agent,
Sporothrix schenckii. S. schenckii exhibits considerable genetic variability, and recently, it
was suggested that this taxon consists of a complex of species. Sporotrichosis is caused
by traumatic inoculation of the fungus, which is a ubiquitous environmental saprophyte
that can be isolated from soil and plant debris. The infection is limited to cutaneous forms,
but recently, more severe clinical forms of this mycosis have been described, especially
among immunocompromised individuals. The immunological mechanisms involved in
the prevention and control of sporotrichosis are not well understood. Some studies
suggest that cell-mediated immunity plays an important role in protecting the host
against S. schenckii. In contrast, the role of the humoral immune response in protection
against this fungus has not been studied in detail. In a previous study, we showed that
antigens secreted by S. schenckii induced a specific humoral response in infected animals,
primarily against a 70-kDamolecule, indicating a possible role of specific antibodies against
this molecule in infection control. In another study by our group, we produced a mAb
against a 70-kDa glycoprotein of S. schenckii to better understand the effect of the
passive immunization of mice infected with S. schenckii. The results showed a significant
reduction in the number of CFUs in various mice organs when the mAb was injected
before or during S. schenckii infection. Similar results were observed when T-cell-deficient
mice were used. The drugs of choice in the treatment of sporotrichosis require long
periods, and relapses are frequently observed, primarily in immunocompromised patients.
The strong protection induced by the mAb against a 70-kDa glycoprotein makes it a strong
candidate as a therapeutic vaccine against sporotrichosis.
Keywords: fungal infection, immunology, medical mycology, monoclonal antibody, sporothrix, sporotrichosis,
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INTRODUCTION
Sporotrichosis is a chronic fungal infection that is endemic to
Brazil, and it is the most common subcutaneous mycosis in South
America (Schubach et al., 2008). The disease is mainly caused by
the dimorphic fungus Sporothrix schenckii. In its saprophytic stage
or when cultured at 25◦C, it assumes a filamentous form, and at
37◦C, it assumes a yeast form (Bustamante and Campos, 2001;
Barros et al., 2011). Sporothrix is widely distributed in nature and
exists in a saprophytic mycelial form in plant debris and soil. The
traumatic inoculation of the conidia and hyphae of this fungus
results in the development of subcutaneous mycoses; within the
infected tissue, the fungus differentiates into its yeast form and
may spread to other tissues (Ramos-e-Silva et al., 2007; Barros
et al., 2011). Since the 1980s, domestic cats have been a source of
mycosis transmission to humans (Nusbaum et al., 1983; Dunstan
et al., 1986a,b; Larsson et al., 1989; Fleury et al., 2001). The largest
epidemic of sporotrichosis due to zoonotic transmission was
described in Rio de Janeiro between 1998 and 2004, in which 759
humans were diagnosed with sporotrichosis (Barros et al., 2004;
Freitas et al., 2010). Recently, Marimon et al. (2007) suggested
that S. schenckii should not be considered the only species that
causes sporotrichosis on the basis of a combination of phenotypic
and genetic features. The group described four new species: S. glo-
bosa, S. brasiliensis, S. mexicana, and S. luriei (Marimon et al.,
2008). These new species have been defined as having a world-
wide distribution, whereas S. brasiliensis is apparently restricted
to Brazil, and S. mexicana is restricted to Mexico. Due to difficul-
ties in classifying strains belonging to the Sporothrix complex, the
same group (Marimon et al., 2008) proposed an identification key
that includes the analysis of conidial morphology, auxanogram
analysis using raffinose and sucrose and genotyping via poly-
merase chain reaction (PCR) amplification of the calmodulin
gene.
Sporotrichosis has diverse clinical manifestations. The most
frequent clinical form (approximately 80% of cases) is the lym-
phocutaneous form (Bonifaz and Vazquez-Gonzalez, 2010). It
starts with a nodular or ulcerated lesion at the site of fungal
inoculation and follows a regional lymphatic trajectory char-
acterized by nodular lesions that ulcerate, fistulate, and heal,
representing true gummae. Another common clinical manifes-
tation is the fixed cutaneous form. In general, the fixed cuta-
neous form is characterized by infiltrated nodular, ulcerated,
or erythematosquamous lesions located on exposed areas on
which the fungal inoculation occurred (Schechtman, 2010). The
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systemic form of sporotrichosis may evolve from an initial cuta-
neous lesion or be associated with the inhalation of conidia
(Gutierrez-Galhardo et al., 2010). More severe clinical forms
of this disease have been associated with immunocompromised
patients, such as human immunodeficiency virus (HIV)-infected
patients, suggesting that S. schenckii is an emerging opportunis-
tic pathogen (Galhardo et al., 2010). In contrast, disseminated
cutaneous sporotrichosis has been reported in an immunocom-
petent individual (Yap, 2011), which demonstrates that although
it is common in immunosuppressed patients, disseminated cuta-
neous sporotrichosis can also present in immunocompetent
patients.
Different drug protocols are used for the treatment of sporotri-
chosis, including potassium iodide, itraconazole, terbinafine, flu-
conazole, and amphotericin B (Song et al., 2011). The treatment
choice is based on the individual’s clinical condition, the extent
of the cutaneous lesions, the assessment of drug interactions and
adverse events, and systemic involvement. Some adverse events,
such as nausea, vomiting and diarrhea, headache, abdominal
pain, hypersensitivity reactions, and liver dysfunction, may be
observed (Lopez-Romero et al., 2011).
Both the pathogenic characteristics of the individual
S. schenckii strains and the immunologic status of the host can
determine the clinical manifestations of sporotrichosis. However,
the factors involved in the pathogenesis of S. schenckii and
mechanisms to determine the strain’s virulence remain unclear.
IMMUNE RESPONSE
The host defense against pathogenic microorganisms includes
innate and acquired immunity. The innate immune system is the
first line of defense against invading pathogens; it is activated
within minutes after the invasion of the host and is responsi-
ble for defense during the initial hours and days of the infec-
tion. In contrast to the rapid activation of the innate immune
system, the activation of specific acquired immunity, which is
primarily mediated by T and B lymphocytes, requires at least
7–10 days before a proper cellular or humoral response occurs.
The ability to discriminate “non-self” from “self” is an essen-
tial component of innate immunity and is achieved through
germ line-encoded receptors that recognize highly conserved
microbial structures: pathogen-associated molecular patterns
(PAMPs).
Several classes of recognition receptors mediate the recogni-
tion of fungal pathogens. Because of the structure of the fungal
cell wall, which is mainly composed of carbohydrate chains,
such as mannans and glucans, the first group of fungal recog-
nition receptors discovered was the lectin receptors (Brown,
2008; Netea et al., 2008). PAMPs are recognized by pattern
recognition receptors (PRRs), which are expressed on various
antigen-presenting cells (APCs), such as dendritic cells (DC)
and macrophages. PRRs play an important role in recognizing
microbial pathogens, activating the innate immune system, and
releasing pro-inflammatory cytokines.
Recent studies have demonstrated that lipid extracts from the
yeast form of S. schenckii bind to TLR4, and this interaction leads
to the induction of an oxidative burst against the fungus (Sassa
et al., 2012).
Uenotsuchi et al. (2006) showed that S. schenckii of cuta-
neous origin but not visceral origin binds to TLR2 and/or TLR4
and induces JNK, ERK, and p38 MAPK activation and IL-6
and TNF-α release. Although both TLR2 and TLR4 ligation can
induce these pro-inflammatory cytokines, TLR2 signals are also
known to mediate an anti-inflammatory effect by directing the
release of IL-10. Thus, the authors speculate that TLR4 but not
TLR2 might be the main receptor for recognizing S. schenckii of
cutaneous origin and inducing a strong Th1 immune response.
T cell-mediated immunity has been described as being fun-
damental in the defense against S. schenckii. In experimental
infections, nude mice are more susceptible to sporotrichosis, and
acquired immunity against S. schenckii is primarily mediated by
macrophages that have been activated by T cells (Hachisuka and
Sasai, 1981). Both CD4+ T cells and macrophages are required
in the granulomatous skin lesions of sporotrichosis; the presence
of IFN-γ-producing CD4+ T cells is an essential component of
host defense against this pathogen (Tachibana et al., 1999). These
findings indicate that the Th1 response mediates granuloma
formation in sporotrichosis.
Cell-mediated and innate immunity are considered the most
important mechanisms of host defense against fungal infections.
In contrast, the role of the humoral immune response in pro-
tection against this fungus has not been studied in detail. Recent
studies have demonstrated that antibodies with defined specificity
show different degrees of protection against mycosis (Casadevall
and Pirofski, 2005). The administration of mAbs-mediated pro-
tection against Paracoccidioides brasiliensis (Buissa-Filho et al.,
2008), Candida albicans (Polonelli et al., 2003), Histoplasma cap-
sulatum (Nosanchuk et al., 2003) and Cryptococcus neoformans
(Rivera et al., 2005) infection in mice.
THERAPEUTIC MONOCLONAL ANTIBODIES AND FUNGAL
INFECTION
Monoclonal antibodies are attractive biologic drugs because
of their specificity and well-understood mechanisms of action,
which result in a higher predictability and lower attrition rate
compared with other drugs. The mechanisms of antibody action
against infectious disease include complement-mediated lysis,
the enhancement or inhibition of phagocytosis, Fc-mediated
cytokine release, and direct antimicrobial effects (Casadevall and
Pirofski, 2005). In terms of fungal infection, it is clear that
antibody-mediated immunity can be decisive for host defense
against C. neoformans (Casadevall and Pirofski, 2012). However,
several factors could affect the function of these antibodies, such
as antibody isotype and quantity.
For many years, the protective role of antibodies in fungal
infection was contested. A consensus has now emerged that the
inability of immune sera to mediate protection against fungi
reflects inadequate amounts of protective antibody and/or the
simultaneous presence of protective and non-protective anti-
bodies rather than a fundamental inability of antibodies to
protect against fungal pathogens. Recently, several studies have
established that some antibodies are protective against fungi
(Xander et al., 2007; Buissa-Filho et al., 2008; Toledo et al., 2010;
Zhang et al., 2011). Moreover, some MAbs designed to pro-
tect against cryptococcosis (Larsen et al., 2005) and candidiasis
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(Pachl et al., 2006) have been approved for clinical evaluation.
An HIV+ patient with cryptococcal meningitis was treated with
the murine MAb 18B7, which is directed against the capsular
polysaccharide of C. neoformans, with excellent results. The MAb
infusion had a half-life in the serum of approximately 53 h and
reduced the fungal circulating antigen (Larsen et al., 2005). The
phase I trial of Mab 18B7 has been completed. Additional phase
II and III studies will be required to demonstrate whether adjunc-
tive therapy with anti-Cryptococcus antibody confers additional
benefit over conventional antifungal therapy. In another study, a
human recombinant MAb to heat shock protein 90 was used in
the treatment of patients with invasive candidiasis (Pachl et al.,
2006). Recently, Krenova et al. (2010) reported the successful
treatment of life-threatening Candida peritonitis in a child with
abdominal non-Hodgkin lymphoma using a MAb against heat
shock protein 90 in association with amphotericin B.
In a previous study, we demonstrated that mice infected with
S. schenckii are able to produce specific IgG1 and IgG3 antibodies
against a 70-kDa fungal protein during experimental infection,
indicating that specific antibodies against this molecule may
participate in controlling infection (Nascimento and Almeida,
2005). To better understand the role of the antibody response in
sporotrichosis, our group produced an IgG1mAb, P6E7, against
a 70-kDa glycoprotein (gp70) of S. schenckii. Immunolocalization
using this anti-gp70 antibody showed that the antigen was pref-
erentially localized on the cell surface and that it could be a
putative adhesin for fibronectin and laminin. To analyze the pro-
tective effect of the mAb in vivo, S. schenckii-infected mice were
passively immunized. Our results showed a significant reduction
in the number of CFUs in the spleen and liver of mice when
the mAb was injected before and during S. schenckii infection
(Nascimento et al., 2008). Furthermore, in a second experiment,
the mAb was injected after infection was established, and again,
we observed a significant reduction in CFUs. IFN-γ was detected
at high levels in the organs of mice that received P6E7. These
results indicate that treatment with the P6E7mAb may induce
a protective cell-mediated immune response via the production
of IFN-γ (Nascimento et al., 2008). In a recent study, our group
showed that yeast cells opsonized with mAbs against gp70 had an
increased phagocytic index and TNF-α production (Franco et al.,
2012).
A possible limitation to the use of vaccines in immunosup-
pressed patients is that these patients may not mount protective
responses, but passive immunization with protective antibodies
may well be a rapid and effective preventive or even thera-
peutic measure. The efficacy of this immunoprophylaxis can be
augmented when it is used in combination with conventional
antifungal therapy. Because the disseminated cutaneous forms of
sporotrichosis have mainly been observed among immunosup-
pressed patients, especially HIV+ individuals, we analyzed the
protective effect of the anti-gp70mAb in deficient nude animals.
We demonstrated that in this model, themAb was efficient at con-
trolling the dissemination of fungal infection (Nascimento et al.,
2008).
The results of these studies may facilitate the development
of an efficient therapy for sporotrichosis. Currently, our labo-
ratory is in the process of developing a humanized P6E7mAb.
The humanized antibodies could be an alternative therapy for the
treatment of patients with sporotrichosis.
CONCLUSION
Therapeutic monoclonal antibodies, which are primarily used as
treatment for cancer and less frequently for infection, are among
the most active area of research and development in the phar-
maceutical industry. mAbs can be used as conjugates with target
drugs and can be fragmented or humanized. A better understand-
ing of the mechanism of action of successful mAbs will be critical
for the development of more active and less toxic mAbs.
The development of a therapeutic vaccine that has the ability to
induce a strong protective response to S. schenckii could therefore
bemore advantageous than existing treatments. The development
of a newmAb-based therapy is an exciting challenge that may lead
to novel approaches in the treatment and immunoprophylaxis of
sporotrichosis.
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